Cargando…

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies

PURPOSE OF REVIEW: Innovative clinical trial designs for glioblastoma (GBM) are needed to expedite drug discovery. Phase 0, window of opportunity, and adaptive designs have been proposed, but their advanced methodologies and underlying biostatistics are not widely known. This review summarizes phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Nicholas S., Wong, Weng Kee, Nghiemphu, Phioanh L., Cloughesy, Timothy F., Ellingson, Benjamin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474988/ https://www.ncbi.nlm.nih.gov/pubmed/37402043 http://dx.doi.org/10.1007/s11912-023-01433-1

Ejemplares similares

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Improving B(0) Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation
por: Yao, Jingwen, et al.
Publicado: (2018)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab
por: Leu, Kevin, et al.
Publicado: (2014)

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
por: Patel, Kunal S., et al.
Publicado: (2020)

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
por: Cloughesy, Tim F, et al.
Publicado: (2008)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
por: Banerjee, Pia, et al.
Publicado: (2015)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
por: Van Dyk, Kathleen, et al.
Publicado: (2022)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI)
por: Wang, Chencai, et al.
Publicado: (2021)

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
por: Ellingson, Benjamin M, et al.
Publicado: (2021)

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study
por: Yao, Jingwen, et al.
Publicado: (2020)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks
por: Wang, Chencai, et al.
Publicado: (2022)

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
por: Ellingson, Benjamin M., et al.
Publicado: (2017)

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
por: Phillips, Patrick P. J., et al.
Publicado: (2019)

Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital “Flipbooks” to Control Systems Theory
por: Ellingson, Benjamin M., et al.
Publicado: (2022)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study
por: Yao, Jingwen, et al.
Publicado: (2022)

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
por: Liu, Vicki, et al.
Publicado: (2023)

Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients
por: Smedley, Nova F., et al.
Publicado: (2018)

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI
por: Hagiwara, Akifumi, et al.
Publicado: (2022)

Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
por: Balasubramanian, Adithya, et al.
Publicado: (2020)

Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease
por: Goldman, Jodi, et al.
Publicado: (2022)

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
por: Chakhoyan, Ararat, et al.
Publicado: (2019)

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
por: Shidoh, Satoka, et al.
Publicado: (2022)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS
por: Peters, Katherine
Publicado: (2022)

The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov
por: Que, Y, et al.
Publicado: (2018)

Window of Opportunity
Publicado: (1996)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

The Skin Microbiome: Current Landscape and Future Opportunities
por: Smythe, Paisleigh, et al.
Publicado: (2023)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study
por: Brenner, Andrew J, et al.
Publicado: (2020)

Gametic phase estimation over large genomic regions using an adaptive window approach
por: Excoffier, Laurent, et al.
Publicado: (2003)

A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
por: Mehta, Shwetal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h9fn2gj85r6e59apdurt24s58o